Annals of Surgical Oncology

, Volume 17, Issue 3, pp 898–906 | Cite as

Hypoxic Single-Pass Isolated Hepatic Perfusion of Hypotonic Cisplatin: Safety Study in the Pig

  • Pablo Ortega-Deballon
  • Olivier Facy
  • David Consolo
  • Guy Magnin
  • Hervé Tixier
  • Michel Simonet
  • Patrick Rat
  • Bruno Chauffert
Translational Research and Biomarkers

Abstract

Background

Isolated hepatic perfusion (IHP) of chemotherapy has been proposed to deliver high doses of drug while avoiding systemic toxicity. Hypotonic cisplatin has a high in vitro activity on human colon cancer cells. We studied the safety of a 30-min hypoxic single-pass IHP with hypotonic cisplatin.

Methods

A preliminary in vitro assay was performed to compare the cytotoxicity of cisplatin and oxaliplatin, in either a normotonic or hypotonic medium. Cisplatin in hypotonic medium was then chosen for the in vivo IHP. Eleven pigs underwent 30 min of IHP with 0, 50, 75, or 100 mg/L of cisplatin in a hypotonic solution under total vascular exclusion of the liver. Clinical and biological parameters were recorded for 30 days, and liver histology was performed at necropsy. The cytotoxic activity of the effluent against resistant human colon cancer cells was tested in vitro.

Results

No hepatic failure was recorded after IHP with cisplatin, but limited foci of necrosis were found at necropsy in animals receiving 75 or 100 mg/L of cisplatin. No clinical, biological, macroscopic, or microscopic toxicity was observed after IHP with 50 mg/L of hypotonic cisplatin. The liver effluent showed high in vitro cytotoxic activity against colon cancer cells.

Conclusions

A hypoxic single-pass isolated liver perfusion with hypotonic cisplatin is feasible and safe. Effluent from the liver is highly cytotoxic on cancer cells. A clinical study with 50 mg/L of hypotonic cisplatin is warranted in patients with unresectable liver metastases from colon cancer.

Keywords

Oxaliplatin Human Colon Cancer Cell Isolate Limb Perfusion Platinum Concentration Hypotonic Medium 

Notes

Acknowledgment

Supported in part by grants from the French National League against Cancer (Committees of Côte d’Or, Saône et Loire and Nièvre) and from the Scientific Committee of the School of Medicine of Dijon (University of Burgundy, France). We thank Jean-Luc Beltramo for measuring platinum concentrations, Laurence Duvillard for determining osmolarity, Pierre-Emmanuel Puig for the in vitro assays, Philippe Pointaire and Jean-Mathieu Ricard for their help during the experiments in the pigs, and Philip Bastable for revising the article in manuscript.

References

  1. 1.
    Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14:3188–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Morise Z, Sugioka A, Kato R, et al. Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg. 2006;10:249–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Noda T, Ohigashi H, Ishikawa O, et al. Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers. Ann Surg. 2007;246:799–805.CrossRefPubMedGoogle Scholar
  4. 4.
    de Vries MR, Borel Rinkes IH, van de Velde CJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 1998;147:107–19.PubMedGoogle Scholar
  5. 5.
    Hafström LR, Holmberg SB, Naredi PL. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994;3:103–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lindnér P, Fjälling M, Hafström L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol. 1999;25:179–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 2000;82:1539–46.CrossRefPubMedGoogle Scholar
  8. 8.
    van Iersel LB, Verlaan MR, Vahrmeijer AL, et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol. 2007;33:874–81.PubMedGoogle Scholar
  9. 9.
    Rothbarth J, Tollenaar RA, van de Velde CJ. Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors. Expert Rev Anticancer Ther. 2006;6:553–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008;24:193–203.CrossRefPubMedGoogle Scholar
  11. 11.
    van Iersel LB, Gelderblom H, Vahrmeijer AL, et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008;19:1127–34.CrossRefPubMedGoogle Scholar
  12. 12.
    van Iersel LB, Hoekman EJ, Gelderblom H, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol. 2008;15:1891–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176–87.CrossRefPubMedGoogle Scholar
  14. 14.
    Alexander HR Jr, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12:138–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Alexander HR Jr, Libutti SK, Bartlett DL, et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer. 2002;95:730–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003;90:1391–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Alexander HR Jr, Bartlett DL, Libutti SK, et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009;16:1852–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Zeh HJ, Brown CK, Holtzman MP, et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009;16:385–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Isambert N, Correia M, Cercueil JP, et al. Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/1 glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study. J Exp Clin Cancer Res. 2001;20:183–8.PubMedGoogle Scholar
  20. 20.
    Smith E, Brock AP. The effect of reduced osmolarity on platinum drug toxicity. Br J Cancer. 1989;59:873–5.PubMedGoogle Scholar
  21. 21.
    Tsujitani S, Fukuda K, Saito H, et al. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery. 2002;131:S98–104.CrossRefPubMedGoogle Scholar
  22. 22.
    Katano K, Tsujitani S, Oka S, et al. Pharmacokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and the pleural cavities in experimental model. Anticancer Res. 2000;20:1603–7.PubMedGoogle Scholar
  23. 23.
    Tsujitani S, Oka A, Kondo A, et al. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology. 1999;57:77–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Kondo A, Maeta M, Oka A, et al. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer. 1996;73:1166–70.PubMedGoogle Scholar
  25. 25.
    van Etten B, de Vries MR, van IJken MG, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer. 2003;88:314–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Savier E, Azoulay D, Huguet E, et al. Percutaneous isolated hepatic perfusion for chemotherapy. A phase I study. Arch Surg. 2003;138:325–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Verhoef C, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases: a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol. 2008;15:1367–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Jungraithmayr W, Szarzynski M, Neeff H, et al. Significance of total vascular exclusion for hepatic cryotherapy: an experimental study. J Surg Res. 2004;116:32–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Miao N, Pingpank JF, Alexander HR, et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol. 2008;15:815–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Sato T, Asanuma Y, Kusano T, et al. Difference in hepatic tissue oxygenation between total vascular exclusion and inflow occlusion of the liver and the possible role of hepatic venous blood under liver ischemia. Dig Surg. 1998;15:15–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Hiratsuka K, Kim YI, Nakashima K, et al. Tissue oxygen pressure during prolonged ischemia of the liver. J Surg Res. 2000;92:250–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Dinant S, Roseboom HJ, Levi M, van Vliet AK, van Gulik TM. Hypothermic in situ perfusion of the porcine liver using Celsior or Ringer-lactate solution. Langenbecks Arch Surg. 2009;394:143–50.CrossRefPubMedGoogle Scholar
  33. 33.
    Heijnen BHM, Straatsburg ICH, Gouma DJ, van Gulik TM. Decrease in core liver temperature with 10°C by in situ hypothermic perfusion under total hepatic vascular exclusion reduces liver ischemia and reperfusion injury during partial hepatectomy in pigs. Surgery. 2003;134:806–17.CrossRefPubMedGoogle Scholar
  34. 34.
    Petrowsky H, McCormack L, Trujillo M, et al. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg. 2006;244:921–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Saidi RF, Chang J, Verb S, et al. The effect of methylprednisolone on warm ischemia-reperfusion injury in the liver. Am J Surg. 2007;193:345–8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Pablo Ortega-Deballon
    • 1
    • 2
  • Olivier Facy
    • 2
  • David Consolo
    • 3
  • Guy Magnin
    • 3
  • Hervé Tixier
    • 1
  • Michel Simonet
    • 4
  • Patrick Rat
    • 1
    • 2
  • Bruno Chauffert
    • 1
    • 5
  1. 1.INSERM UMR 866, School of MedicineUniversity of BurgundyBurgundyFrance
  2. 2.Department of Digestive and Thoracic Surgical OncologyUniversity HospitalDijonFrance
  3. 3.Department of AnesthesiologyUniversity HospitalDijonFrance
  4. 4.Veterinary ClinicNuits Saint GeorgesFrance
  5. 5.Department of Medical OncologyGF Leclerc Regional Anticancer CenterDijonFrance

Personalised recommendations